Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Operating Leases: 2021-2025

Historic Operating Leases for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to $20.4 million.

  • Janux Therapeutics' Operating Leases fell 6.26% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year decrease of 6.26%. This contributed to the annual value of $21.3 million for FY2024, which is 7.60% down from last year.
  • Janux Therapeutics' Operating Leases amounted to $20.4 million in Q3 2025, which was up 0.31% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Operating Leases ranged from a high of $24.5 million in Q4 2022 and a low of $23,000 during Q3 2021.
  • Its 3-year average for Operating Leases is $22.2 million, with a median of $22.2 million in 2024.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 104,647.83% in 2022, then dropped by 8.44% in 2025.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Operating Leases stood at $23,000 in 2021, then spiked by 104,647.83% to $24.5 million in 2022, then dropped by 6.18% to $23.0 million in 2023, then dropped by 7.60% to $21.3 million in 2024, then fell by 6.26% to $20.4 million in 2025.
  • Its Operating Leases stands at $20.4 million for Q3 2025, versus $20.3 million for Q2 2025 and $20.8 million for Q1 2025.